Research Focus On Cognitive Disorders

Cognitive disorders are defined as those in which a limitation of cognitive functioning is the main feature. They include: amnestic disorders, Huntington's disease, and mental retardation, dementia, delirium, aphasia, and cognitive disorders not otherwise specified. This book brings together leading researchers from throughout the world.

Cognitive disorders are defined as those in which a limitation of cognitive functioning is the main feature. They include: amnestic disorders, Huntington's disease, and mental retardation, dementia, delirium, aphasia, and cognitive disorders not otherwise specified. This book brings presents leading researchers from throughout the world.

Societies around the world are concerned about dementia and the other forms of cognitive impairment that affect many older adults. We now know that brain changes typically begin years before people show symptoms, which suggests a window of opportunity to prevent or delay the onset of these conditions. Emerging evidence that the prevalence of dementia is declining in high-income countries offers hope that public health interventions will be effective in preventing or delaying cognitive impairments. Until recently, the research and clinical communities have focused primarily on understanding and treating these conditions after they have developed. Thus, the evidence base on how to prevent or delay these conditions has been limited at best, despite the many claims of success made in popular media and advertising. Today, however, a growing body of prevention research is emerging. Preventing Cognitive Decline and Dementia: A Way Forward assesses the current state of knowledge on interventions to prevent cognitive decline and dementia, and informs future research in this area. This report provides recommendations of appropriate content for inclusion in public health messages from the National Institute on Aging.

Cognitive Enhancement in CNS Disorders and Beyond compiles a series of educational and thought-provoking chapters from the world's leading cognitive and clinical scientists to describe the latest research on cognitive impairments in a host of pathological conditions that affect CNS functioning, what treatments are available for these impairments, and how new treatments are being tested. This volume will benefit any investigators in cognitive science and clinical research, but is also accessible to non-experts. It advances the field toward the availability of cognitive enhancing drugs and devices that will benefit those who need them most and others who may feel that these techniques can help them to thrive. There has never been a time that we knew more about cognition and never a time when cognition was more important to the functioning of human beings than right now. Psychological science and cognitive neuroscience have become the most popular endeavor of students world wide, is the focus of attention of our greatest scientific accomplishments and the emphasis of many publications in the mainstream media. Since humans depend on cognitive abilities for survival, quality of life, and productivity, improving it has never been more important. Those with impairments in key aspects of cognition suffer dearly, as they are unable to obtain and retain information, unable to make sound decisions based upon the information at hand, and unable to plan future activities. The availability of pharmacological and behavioral interventions that can improve cognitive abilities and provide impaired individuals with the social, occupational and functional quality of life that the rest of us enjoy has potential far-reaching implications. Such interventions can also benefit those who want to boost current cognitive abilities to higher levels, perhaps as a means to hone skills in providing products for others or to gain an edge on competition. There has never been a book devoted solely to describing the latest cognitive science and neuroscience on the methods for enhancing cognition in healthy and unhealthy humans. Cognitive Enhancement in CNS Disorders and Beyond accomplishes exactly that in a straightforward and accessible manner.

By 2030 there will be about 70 million people in the United States who are older than 64. Approximately 26 percent of these will be racial and ethnic minorities. Overall, the older population will be more diverse and better educated than their earlier cohorts. The range of late-life outcomes is very dramatic with old age being a significantly different experience for financially secure and well-educated people than for poor and uneducated people. The early mission of behavioral science research focused on identifying problems of older adults, such as isolation, caregiving, and dementia. Today, the field of gerontology is more interdisciplinary. When I'm 64 examines how individual and social behavior play a role in understanding diverse outcomes in old age. It also explores the implications of an aging workforce on the economy. The book recommends that the National Institute on Aging focus its research support in social, personality, and life-span psychology in four areas: motivation and behavioral change; socioemotional influences on decision-making; the influence of social engagement on cognition; and the effects of stereotypes on self and others. When I'm 64 is a useful resource for policymakers, researchers and medical professionals.

Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. The most common form of dementia among older people is Alzheimer's disease (AD), which involves the parts of the brain that control thought, memory, and language. Age is the most important known risk factor for AD. The number of people with the disease doubles every 5 years beyond age 65. AD is a slow disease, starting with mild memory problems and ending with severe brain damage. The course the disease takes and how fast changes occur vary from person to person. On average, AD patients live from 8 to 10 years after they are diagnosed, though the disease can last for as many as 20 years. Current research is aimed at understanding why AD occurs and who is at greatest risk of developing it, improving the accuracy of diagnosis and the ability to identify those at risk, discovering, developing, and testing new treatments, and discovering treatments for behavioural problems in patients with AD. This new book gathers state-of-the-art research from leading scientists throughout the world which offers important information on understanding the underlying causes and discovering the most effective treatments for Alzheimer's Disease.

This book is for individuals with mild cognitive impairment (MCI), their loved ones, and health care professionals who care for these patients. The text is loaded with up-to-date, scientifically substantiated knowledge about what MCI is, how it affects people, and how to take a proactive approach to health and wellbeing for living with MCI.

Cognitive Disorders: Advances in Research and Treatment: 2011 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Delirium, Dementia, Amnestic, Cognitive Disorders in a concise format. The editors have built Cognitive Disorders: Advances in Research and Treatment: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Delirium, Dementia, Amnestic, Cognitive Disorders in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Cognitive Disorders: Advances in Research and Treatment: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.